Roche's prospects look sunnier, thanks to blockbuster-boosting data for Hemlibra, Tecentriq
admin 20th November 2017 Uncategorised 0Two of Roche’s new generation of drugs—including the just-approved hemophilia therapy Hemlibra—racked up new data Monday that bolster their case for blockbuster sales. That’s good for the drugmaker, whose top-selling cancer meds are facing a growing threat from biosimilars.
More: Roche's prospects look sunnier, thanks to blockbuster-boosting data for Hemlibra, Tecentriq
Source: fierce